4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoic acid

CAS: 19741-14-1

Ref. 3D-ID20780

Informação sobre produto

• Nome: 4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoic acid
• Sinónimos: 2,4-Diamino-N10-methylpteroic acidDAMPAMethotrexate impurity E hemihydrochloride hydrate, 4-(N-(2,4-diamino-6-pteridinyl-*methyl)-N-methyl-, 4-(N-(2,4-diamino-6-pteridinylmethyl)*-N-methyl-, Bis(4-((2,4-Diaminopteridin-6-Ylmethyl)Methylamino)Benzoic) Acid Hydrochloride Tetrahydrate, 4-[N-(2,4-Diamino-6-pteridinylmethyl)-N-methylamino]benzoic acid hemihydrochloride dihydrate, 4-{[(2,4-Diaminopteridin-6-Yl)Methyl](Methyl)Amino}Benzoic Acid
• CAS: 19741-14-1

Descrição

4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoic acid is a drug with low bioavailability. It is used to treat leishmaniasis, an infection caused by the parasite Leishmania. 4-[[(2,4-Diamino-6-pteridinyl)methyl]methylamino]benzoic acid inhibits the synthesis of folic acid by blocking the enzyme dihydrofolate reductase in the bacteria. This drug also has been shown to be effective against autoimmune diseases and inflammatory bowel disease. The terminal half-life of 4-[(2,4-diamino6 pteridinyl)methyl]methylamino benzoic acid is approximately 5 hours and it can be detected in urine for up to 12 hours after administration.

• Marca: Biosynth

Propriedades químicas

• Peso molecular: 325.33 g/mol
• Fórmula: C₁₅H₁₅N₇O₂
• Pureza: (1H-Nmr) Min. 95 Area-%
• Cor/forma: Brown Yellow Powder